FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308871954> ?p ?o ?g. }

• W4308871954 abstract "Background Therapies based on the combination of immune checkpoint inhibitors (ICIs) and thoracic radiotherapy (TRT) are transforming the treatment landscape of esophageal cancer. Nevertheless, the available data on adverse events (AEs) mainly stemmed from several prospective clinical trials and retrospective studies, in which, AE data are often handled and reported with less rigor than the primary beneficial outcomes of the study. Thus, we conducted a systematic review to investigate the toxicity spectrum of these novel regimens. Method We searched for all prospective clinical trials investigating the role of ICIs combined with TRT published between January 2010 and August 2022. Study articles and conference proceedings involving esophageal cancers and reporting the overall incidence or details of treatment-related AEs (trAEs) were synthesized to determine the toxicity profile of combination treatment. We compared trAEs between cancer type, programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, and between sequential and concurrent administration of ICIs and TRT to identify potentially high-risk patients. Results We obtained toxicity data from 14 clinical trials involving 863 patients. The pooled overall incidence was 88.97% for any-grade trAEs and 18.48% for high-grade trAEs. The three most frequent non-hematologic any-grade trAEs were reactive cutaneous capillary endothelial proliferation (RCCEP, 63.80%), esophagitis (51.54%), and fatigue (33.63%). Meanwhile, RCCEP (15.69%) was the most common non-hematologic high-grade trAE, followed by nausea (4.91%) and anorexia (3.81%). The occurrence rates of any-grade and high-grade pneumonitis were 10.82% and 0.66%, respectively. In subgroup analysis, the toxicity profiles of PD-1 and PD-L1 inhibitors were mostly similar, except for any-grade pneumonitis (15.20% vs 4.88%, p=0.03) and high-grade leukopenia (6.25% vs 59.09%, p=0.00). In addition, concurrent treatment seemed to have a higher incidence of any-grade trAEs (95.20% vs 70.85%, p=0.03) compared with sequential treatment. ESCC seems to have higher incidence of any-grade hypothyroidism (22.55% vs 8.96%, p=0.049) compared to EAC. Conclusion Our study is the first systematic review to provide a toxicity profile of trAEs in esophageal cancer patients who received ICIs combined with TRT. Most AEs of this combination treatment are tolerable, although the incidence of any-grade trAEs was higher in the concurrent group. The difference in any-grade pneumonitis between PD-1 and PD-L1 inhibitor groups needs further validation in a large clinical trial." @default.
• W4308871954 created "2022-11-18" @default.
• W4308871954 creator A5022309361 @default.
• W4308871954 creator A5043817290 @default.
• W4308871954 creator A5045899101 @default.
• W4308871954 creator A5081853954 @default.
• W4308871954 date "2022-11-10" @default.
• W4308871954 modified "2023-10-02" @default.
• W4308871954 title "Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review" @default.
• W4308871954 cites W1043337635 @default.
• W4308871954 cites W1969113457 @default.
• W4308871954 cites W1994839187 @default.
• W4308871954 cites W2017044005 @default.
• W4308871954 cites W2022539637 @default.
• W4308871954 cites W2030553697 @default.
• W4308871954 cites W2039612753 @default.
• W4308871954 cites W2122166737 @default.
• W4308871954 cites W2125435699 @default.
• W4308871954 cites W2140625837 @default.
• W4308871954 cites W2144263975 @default.
• W4308871954 cites W2147311753 @default.
• W4308871954 cites W2148361291 @default.
• W4308871954 cites W2154444715 @default.
• W4308871954 cites W2157823046 @default.
• W4308871954 cites W2230150749 @default.
• W4308871954 cites W2324592094 @default.
• W4308871954 cites W2347070489 @default.
• W4308871954 cites W2465249712 @default.
• W4308871954 cites W2567362164 @default.
• W4308871954 cites W2594042408 @default.
• W4308871954 cites W2736618404 @default.
• W4308871954 cites W2753065806 @default.
• W4308871954 cites W2756648224 @default.
• W4308871954 cites W2767702561 @default.
• W4308871954 cites W2805209851 @default.
• W4308871954 cites W2885107163 @default.
• W4308871954 cites W2893242589 @default.
• W4308871954 cites W2896550213 @default.
• W4308871954 cites W2897874271 @default.
• W4308871954 cites W2935875088 @default.
• W4308871954 cites W2947159988 @default.
• W4308871954 cites W2968968778 @default.
• W4308871954 cites W2975424845 @default.
• W4308871954 cites W2978795816 @default.
• W4308871954 cites W2997719187 @default.
• W4308871954 cites W3015126898 @default.
• W4308871954 cites W3026296708 @default.
• W4308871954 cites W3032571309 @default.
• W4308871954 cites W3080657172 @default.
• W4308871954 cites W3093673252 @default.
• W4308871954 cites W3115014139 @default.
• W4308871954 cites W3118615836 @default.
• W4308871954 cites W3121421447 @default.
• W4308871954 cites W3148827278 @default.
• W4308871954 cites W3173451714 @default.
• W4308871954 cites W3182963094 @default.
• W4308871954 cites W3188668978 @default.
• W4308871954 cites W3189379297 @default.
• W4308871954 cites W3198066289 @default.
• W4308871954 cites W3199275245 @default.
• W4308871954 cites W3200755631 @default.
• W4308871954 cites W3201991314 @default.
• W4308871954 cites W3202549400 @default.
• W4308871954 cites W3209651782 @default.
• W4308871954 cites W4205400526 @default.
• W4308871954 cites W4206097172 @default.
• W4308871954 cites W4211191785 @default.
• W4308871954 cites W4214669832 @default.
• W4308871954 cites W4229046570 @default.
• W4308871954 cites W4285490947 @default.
• W4308871954 cites W4286295727 @default.
• W4308871954 cites W49437421 @default.
• W4308871954 doi "https://doi.org/10.3389/fimmu.2022.1039020" @default.
• W4308871954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36439117" @default.
• W4308871954 hasPublicationYear "2022" @default.
• W4308871954 type Work @default.
• W4308871954 citedByCount "3" @default.
• W4308871954 countsByYear W43088719542023 @default.
• W4308871954 crossrefType "journal-article" @default.
• W4308871954 hasAuthorship W4308871954A5022309361 @default.
• W4308871954 hasAuthorship W4308871954A5043817290 @default.
• W4308871954 hasAuthorship W4308871954A5045899101 @default.
• W4308871954 hasAuthorship W4308871954A5081853954 @default.
• W4308871954 hasBestOaLocation W43088719541 @default.
• W4308871954 hasConcept C121608353 @default.
• W4308871954 hasConcept C126322002 @default.
• W4308871954 hasConcept C143998085 @default.
• W4308871954 hasConcept C197934379 @default.
• W4308871954 hasConcept C2777714996 @default.
• W4308871954 hasConcept C2779524853 @default.
• W4308871954 hasConcept C2779742542 @default.
• W4308871954 hasConcept C2780580376 @default.
• W4308871954 hasConcept C29730261 @default.
• W4308871954 hasConcept C535046627 @default.
• W4308871954 hasConcept C71924100 @default.
• W4308871954 hasConcept C90924648 @default.
• W4308871954 hasConceptScore W4308871954C121608353 @default.
• W4308871954 hasConceptScore W4308871954C126322002 @default.
• W4308871954 hasConceptScore W4308871954C143998085 @default.
• W4308871954 hasConceptScore W4308871954C197934379 @default.

• next